Leukemia: Genetics and prognostic factors

Jornal de Pediatria

Volumn 84, Issue 4 SUPPL., 2008, Pages

  Hamerschlak, Nelson ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Cytogenetics; Genetics; Leukemia; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; CYTARABINE; DAUNORRUBICIN; DOXORUBICIN; HYDROCORTISONE; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RETINOIC ACID; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD TESTIS BARRIER; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLONE; CYTOGENETICS; GENE MUTATION; HUMAN; KARYOTYPE; ONCOGENE; PROGNOSIS; REVIEW; RISK ASSESSMENT;

CYTOGENETIC ANALYSIS; HUMANS; LEUKEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 57549110462     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1785     Document Type: Review

References (30)

1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science. 1960;132:1497.
2. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst. 1961;27:1013-35.
3. Thiesing JT, Ohno-Jones S, Kolibaba AS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96:3195-9.
4. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115-36.
5. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154-63.
6. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk adapted treatment of acute promyelocitic leukemia with all trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by PETHEMA group. Blood. 2004;103:1237-43.
7. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21:2123-37.
8. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in AcuteMyeloid Leukemia. J Clin Oncol. 2003;21:4642-9.
9. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Blood. 2005;23:482-93.
10. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in acutemyeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-48.
11. Mrozek K, Bloomfield C. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006:169-77.
12. Shih LY, Liang DC, Huang CF, Chang YT, Lai CL, Lin TH, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008;22:303-7.
13. Andersson A, Paulsson K, Lilljebjörn H, Lassen C, Strömbeck B, Heldrup J, et al. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns. Genes Chromosomes Cancer. 2008;47:64-70.
14. Shimada A, Taki T, Tabuchi K, Taketani T, Hanada R, Tawa A, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhoodAMLCooperative Study Group. Pediatr Blood Cancer. 2008;50:264-9.
15. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD; National Comprehensive Cancer Network, et al. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007;5:474-96.
16. National Comprehensive Cancer Network. Chronicmyelogenous leukemia clinical practice guidelines in oncology (version 1.2008). http://www.nccn.org.
17. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
18. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al;European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-20.
19. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143-50.
20. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-13.
21. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-22.
22. Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16:1402-11.
23. Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program. 2007;2007:384-91.
24. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926-32.
25. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA. 2006;103:19466-71.
26. a ed. São Paulo: Sarvier; 2003. p. 274-9.
27. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-15.
28. Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696-707.
29. Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094-6.
30. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemias. Hematology Am Soc Hematol Educ Program. 2004:118-45.